Aetna Bundles Cancer Prior Authorizations Into One Request

CVS Health's Aetna is combining prior authorization requests for cancer treatment into a single upfront submission instead of requiring doctors to file separate approval requests at each stage of care, according to a report from Healthcare Dive published Sept. 17, 2026. Aetna is a national health insurer owned by CVS Health that sells Medicare Advantage, Medicare Supplement, and commercial health plans. Prior authorization is the requirement that a health plan approve a treatment, test, or procedure before it agrees to pay for it.

According to Aetna, the bundled approach is meant to cut back on the paperwork oncologists submit when a cancer diagnosis leads to multiple treatments, such as surgery, chemotherapy, radiation, and follow-up imaging, over the course of a patient's care. The source material reviewed for this article does not specify which Aetna plan types, including whether Medicare Advantage members are included in the initial rollout, or give an effective date for the change.

How the Bundled Authorization Process Works

Under the process Aetna is replacing, oncology practices have often needed to request authorization separately at each phase of a treatment plan. Providers and medical groups have said that step-by-step approval requirements can contribute to delays in starting or continuing cancer treatment while a plan reviews each new request. Aetna's bundled model groups the preapproval steps a cancer patient is likely to need into one review, so a single decision can authorize a fuller course of treatment rather than a series of individual approvals tied to each visit or procedure.

Aetna frames the change as an effort to reduce administrative burden for treating physicians, per Healthcare Dive's reporting. The company has not published, in the material available for this analysis, a specific number of cancer types covered or a rollout schedule across its different lines of business.

Key Takeaway

Medicare Advantage enrollees undergoing or anticipating cancer treatment should ask their plan and oncology office directly whether Aetna's bundled authorization process applies to their specific plan. Prior authorization rules can vary by plan type, region, and diagnosis even within the same insurer, so this change should not be assumed to apply automatically to every Aetna Medicare Advantage member.

What It Could Mean for Medicare Advantage Members

Prior authorization delays are among the most common complaints associated with Medicare Advantage, the privately administered alternative to Original Medicare that frequently requires plan approval before covering certain services. The Centers for Medicare & Medicaid Services (CMS), the federal agency that oversees Medicare, has pushed insurers in recent years to speed up prior authorization decisions and reduce paperwork for patients and providers across Medicare Advantage plans. If Aetna extends its bundled cancer authorization model to its Medicare Advantage members, the change could reduce the number of separate approval requests an oncology team has to submit for a single patient, which could shorten gaps between one phase of treatment and the next.

That said, until Aetna or plan-level coverage documents confirm Medicare Advantage inclusion, beneficiaries should not assume the streamlined process applies to their own policy. Prior authorization requirements, timelines, and appeal rights are typically detailed in a plan's Evidence of Coverage document, and they can change from one plan year to the next even for members who stay with the same insurer.

For Medicare beneficiaries comparing Medicare Advantage or Part D options, prior authorization policy is one factor worth weighing alongside premiums, provider networks, and drug formularies, particularly for anyone with a current or recent cancer diagnosis or a family history that raises the likelihood of needing cancer-related care.

What Medicare Advantage Enrollees Should Do Next

Readers who are current Aetna members or considering an Aetna Medicare Advantage plan can take a few concrete steps:

Call Aetna member services or review the plan's Evidence of Coverage document to confirm whether the bundled cancer authorization process applies to your specific plan and service area. Ask your oncologist's office whether it has already seen changes in how Aetna processes preapproval requests for cancer treatment. If you plan to shop for coverage during the Medicare Advantage Annual Enrollment Period, which runs Oct. 15 through Dec. 7, 2026, for coverage starting Jan. 1, 2027, ask any insurer you're considering how it specifically handles prior authorization for multi-phase cancer care rather than relying on a plan's general prior authorization summary. A licensed Medicare agent can help compare how competing plans handle prior authorization for complex treatments, since this level of detail is not always included in standard plan comparison tools. Readers can review the original Healthcare Dive report linked above for further detail on Aetna's announcement as more specifics become available.